Atlanta, USA – July 6, 2017 – SAH Global, an international leader in Proton Therapy cancer treatment, has announced the signing of a Memorandum of Understanding (MOU) with ECS-Screening, the creator of the DECODE Lab, an early cancer screening test that detects cancer before symptoms appear. These two leaders in cancer detection and treatment will now collaborate to establish clinical studies and further research that will examine the clinical value of the DECODE Lab in Proton Therapy clinical protocols.
SAH Global is an international Proton Therapy company working to revolutionize cancer treatment in the Middle East. The company has developed a network of world-class Proton Therapy and PET & Molecular centers throughout the MENA region to meet the growing global demand for innovative cancer care.
Proton Therapy is highly effective at targeting cancerous cells while limiting damage to surrounding healthy tissues. It is one of the most effective forms of cancer treatment available today and is especially successful in shrinking and killing localized cancers. Because it is more precise and limits damage to healthy tissue and organs, Proton Therapy patients experience fewer side effects and less pain.
SAH Global is at the forefront of using Proton Therapy in innovative ways to fight a variety of cancers including brain and spine, breast, gastro-intestinal, head and neck, lung, prostate, other adult and pediatric cancers. Studies have shown that Proton Therapy may also significantly decrease the estimated risk of developing secondary malignancies.
ECS-Screening developed the first early cancer screening that can detect multiple cancers before symptoms appear. Called DECODE Lab it detects a specific cancer biomarker in the blood called Progastrin. The DECODE Lab screening test presents an innovative and long-sought after solution to early stage cancer detection that is simple, reliable, reproducible, cheap and valid for multiple cancers. The screening tests that are currently used widely cannot detect several types of cancer and do not allow for efficient detection of tumors in early stages.
ECS-Screening solved the early cancer detection problem when it discovered that in almost all types of cancers, at the earliest stages of development, there is a secretion of Progastrin by cancer cells. The gene coding for progastrin is a direct target gene of the Wnt/ß-catenin pathway that is activated in almost all human tumors and that supports the expression of multiple cancer genes that are required for cancer cells to grow and survive.
With the signing of the MOU, SAH Global and ECS-Screening have come together to use their expertise to apply DECODE Lab to Proton Therapy clinical protocols in order to greatly improve therapy monitoring and patient follow up. The ECS-Screening early detection of cancer before symptoms appear, along with Proton Therapy’s precise targeting and treatment of cancerous tumors presents a ground-breaking opportunity to dramatically decrease global cancer mortality.
About Proton Therapy
Proton Therapy is the most advanced form of cancer treatment available today. With a success rate of up to 96%, this form of radiotherapy is unique in its accuracy and in its heightened ability to avoid damage to healthy cells or tissues during treatment. On average, Proton Therapy will treat 70% less healthy tissues as compared to conventional radiation therapy. To learn more log onto https://www.sahglobal.com/proton-therapy/
About SAH Global
Strategic Alliance Holdings Global, LLC (“SAH Global”), is a holding company founded in 2005 to manage highly specialized investment projects within a variety of sectors, including software development, communications, healthcare, energy and real estate. The company targets projects based on their long-term growth prospects, their use of cutting-edge technologies, to positively impact the global community as a whole. The management team is a group of seasoned veterans from multiple industries led by founder, Mr. Feroz Agad, a seasoned entrepreneur with a strong track record of successfully implementing and leading new business ventures and taking these to profitability.
ECS Screening is a late pre-commercial stage biotechnology company that has leveraged over 10 years of R&D to develop its core assets around a novel target (Progastrin), which is produced in high levels by cancer stem cells but not by healthy cells. They have recently emerged from “stealth mode” after developing their proprietary first product – DECODE Lab – a quantitative ELISA based test intended for cancer therapy monitoring, diagnosis and screening purposes. The company has progastrin data from over 1400 samples including 600 cancer patients and recently validated their test performance in multiple solid cancers including breast, colorectal and melanoma. They are anticipating CE mark approval in mid-to-late 2017. To learn more about ECS-Screening, visit http://www.ecs-screening.ch